Story at-a-glance
- Ozempic, a diabetes drug now used for weight loss, is part of a massive fraud that could harm millions, especially children, by treating obesity without addressing its root causes
- The obesity epidemic is driven in part by ultraprocessed foods designed to override natural satiety mechanisms, not by a lack of weight loss drugs like Ozempic
- The Treat and Reduce Obesity Act could mandate government coverage for obesity medications for 74% of Americans, costing over $3 trillion annually without addressing underlying health issues
- Ozempic’s maker, Novo Nordisk, has become a top lobbying spender in the U.S., pushing for expanded drug coverage while downplaying significant side effects like muscle loss, suicidal thoughts and increased cancer risk
- Naturally increasing GLP-1 levels through gut bacteria like Akkermansia muciniphila offers an alternative to Ozempic, promoting overall gut health without the risks associated with long-term pharmaceutical use